MYRIAD GENETICS, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | $233.5M | $1.09B | $93.2M |
| FY2020 | $224.4M | $918.2M | $163.7M |
| FY2021 | $0 | $967.8M | $257.4M |
| FY2022 | $0 | $885.8M | $56.9M |
| FY2023 | $38.5M | $783.2M | $132.1M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | $233.5M | $1.09B | $93.2M |
| FY2020 | $224.4M | $918.2M | $163.7M |
| FY2021 | $0 | $967.8M | $257.4M |
| FY2022 | $0 | $885.8M | $56.9M |
| FY2023 | $38.5M | $783.2M | $132.1M |